Back to search results

Supplemental Oxygen for Pulmonary Hypertension During Dialysis

This study is looking at whether giving supplemental oxygen during hemodialysis (a treatment for kidney failure) can help people who have pulmonary hypertension (high blood pressure in the lungs) and intradialytic hypoxemia (low oxygen levels during dialysis). Researchers want to see if it's practical to give oxygen using an oxygen concentrator compared to breathing room air. You might be able to join if you are an adult, receive hemodialysis on specific days, and have been found to have pulmonary hypertension and low oxygen levels during dialysis. The main goal is to see how much the daily low oxygen burden changes over three weeks. The study plans to enroll 10 people, and its current status is unclear.

Study design
This is an interventional study with a planned enrollment of 10 participants. It compares supplemental oxygen delivered by an oxygen concentrator to room air.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures changes in daily hypoxemia burden at Weeks 1, 2, and 3.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06327373

A Feasibility Study of Supplemental Oxygen to Improve Pulmonary Hypertension in People With Intradialytic Hypoxemia

Not Yet Recruiting
PHASE1Ages 18+InterventionalTreatment
Duke University
~10 participants
Updated 2025-08-27 on ClinicalTrials.gov
What's tested:OxygenRoom air

At a glance

Recruiting sites
0 of 11 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change daily hypoxemia burden
Measured over Weeks 1, 2, and 3

Conditions

Pulmonary Hypertension

Explore related trials

Pulmonary Hypertension

Where it's being run

11 sites across 1 states
North Carolina11

Study leadership

  • Daniel Edmonston, MD, MHS · PRINCIPAL_INVESTIGATOR · Duke University

Who to contact

Anastacia Bohannon
[email protected]
919-668-3376
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults ≥18 years
Receiving Monday-Wednesday-Friday or Tuesday-Thursday-Saturday hemodialysis
Screened positive for pulmonary hypertension (defined by tricuspid regurgitant velocity \[TRV\] \>2.5 m/s on echocardiography) and intradialytic hypoxemia (defined by spending ≥1/3 treatment with O2 saturation \<90%) or hypoxemia for ≥10% of the treatment if associated with a desaturation event (≥4% decline in O2 saturation to \<88% for ≥10 seconds) during enrollment in the PH-ESKD study (Pro00108710).

Exclusion

Daily supplemental oxygen use
Inability to provide informed consent

What this trial measures

  • Change daily hypoxemia burdenWeeks 1, 2, and 3

    Minutes with oxygen saturation \<90% over a 24-hour period assessed by pulse oximetry